statnews.com·Mar 18, 2026
Azalea Therapeutics has demonstrated early success in developing in vivo CAR-T therapy, a method that involves engineering immune cells directly within the patient's body using precise gene editing, potentially expanding access and reducing costs for cancer treatments.
Azalea Therapeutics has demonstrated early success in engineering CAR-T cells in vivo using precise gene editing, potentially revolutionizing access to cancer treatments by eliminating the need for external cell manipulation. This development could significantly reduce costs and expand access to CAR-T therapies, presenting a promising investment signal for stakeholders in biotech and healthtech sectors focusing on innovative cancer treatments.